p53 website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis

Human Mutation

Volumn 15, Issue 1, 2000, Pages 105-113

  Soussi, Thierry ^a,c   Dehouche, Karim ^a   Béroud, Christophe ^b  

^a CNRS   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSTITUT CURIE   (France)

Author keywords

Cancer; Carcinogenesis; Epidemiology; Locus specific database; MDI; Mutation database; p53; PT53; UMD

Indexed keywords

AFLATOXIN; PROTEIN P53;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER GENETICS; COMPUTER PROGRAM; DATA ANALYSIS; DISEASE ASSOCIATION; GENETIC LINKAGE; HUMAN; HUMAN CELL; LIVER CARCINOMA; LUNG CANCER; PRIORITY JOURNAL; SKIN CANCER; SMOKING; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DATABASE MANAGEMENT SYSTEMS; EPIDEMIOLOGY, MOLECULAR; GENES, P53; HUMANS; INTERNET; MUTATION; NEOPLASMS;

NICOTIANA TABACUM;

EID: 0033986412     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G     Document Type: Article

References (56)

1. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti R 1994. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 264:1317-1319.
2. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. 1995. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1:1029-1034.
3. Béroud C, Soussi T. 1998. p53 Gene mutation: software and database. Nucleic Acids Res 26:200-204.
4. Béroud C, Collod-Béroud G, Boileau C, Soussi T, Junien C. 2000. UMD (universal mutation database): a generic software to build and analyze locus-specific databases. Hum Mutat 15: 86-94.
5. Brash DE, Rudolph JA, Simon JA, Lin A, Mckenna GJ, Baden HR Halperin AJ, Ponten J. 1991. A role for sunlight in skin cancer - UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88:10124-10128.
6. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA, Sidransky D. 1995. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332:712-717.
7. Bressac B, Kew M, Wands J, Ozturk M. 1991. Selective G-mutation to T-mutation of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429-431.
8. Caron de Fromentel C, Soussi T. 1992. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosom Cancer 4:1-15.
9. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ. 1996. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13:1971-1981.
10. Chiba I, Takahashi T, Nau MM, d'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbon D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC, Minna JD. 1990. Mutations in the p53 gene are frequent in primary, resected non-small-cell lung cancer. Oncogene 5:1603-1610.
11. Cho YJ, Gorina S, Jeffrey PD, Pavletich NP. 1994. Crystal structure of a p53 tumor suppressor DNA complex: understanding tumorigenic mutations. Science 265:346-355.
12. Cotton RGH, Horaitis O. 2000. Quality control in the discovery, reporting, and recording of genomic variation. Hum Mutat 15:16-21.
13. Doll R, Peto R. 1981. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Nat Cancer Inst 66:1192-1308.
14. Dumaz N, Stary A, Soussi T, Dayagrosjean L, Sarasin A. 1994. Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene? Mutat Res 307:375-386.
15. Felix CA, Strauss EA, Damico D, Tsokos M, Winter S, Mitsudomi T, Nau MM, Brown DL, Leahey AM, Horowitz ME, Poplack DG, Costin D, Minna JD. 1993. A novel germline p53 splicing mutation in a pediatric patient with a 2nd malignant neoplasm. Oncogene 8:1203-1210.
16. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR. 1997. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 94:10895-10900.
17. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher JM, Bron L, Benhattar J, Tada M, Vanmeir EG, Estreicher A, Iggo RD. 1995. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92:3963-3967.
18. Foti A, Bareli M, Ahuja HG, Cline MJ. 1990. A splicing mutation accounts for the lack of p53 gene expression in a CML blast crisis cell line - a novel mechanism of p53 gene inactivation. Br J Haematol 76:143-145.
19. Gejman PV, Cao Q, Guedj F, Sommer S. 1998. The sensitivity of denaturing gradient gel electrophoresis: a blinded analysis. Mutat Res 382:109-114.
20. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
21. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G. 1994. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106:42-48.
22. Harris CC. 1991. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 51:5023s-5044s.
23. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA. 1995. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53 deficient mice. Nat Genet 9:305-311.
24. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49-53.
25. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. 1991. Mutational hotspot in the p53 gene in human hepato-cellular carcinomas. Nature 350:427-428.
26. IARC. 1990. Cancer: causes, occurence and control. 10: Lyon, France: IARC.
27. Ishioka C, Frebourg T, Yan Y, Vidal M, Friend SH, Schmidt S, Iggo R. 1993. Screening patients for heterozygotous p53 mutations using a functional assay in yeast. Nat Genet 5: 124-129.
28. Jayaraman L, Prives C. 1995. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81:1021-1029.
29. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, Leffell DJ, Tarone RE, Brash DE. 1996. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 93:14025-14029.
30. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
31. Lane D. 1992. p53, Guardian of the genome. Nature 358:15-16.
32. Lee S, Elenbaas B, Levine A, Griffith J. 1995. p53 and its 14 kDa c-terminal domain recognize primary DNA damage in the form of insertion deletion mismatches. Cell 81:1013-1020.
33. Leejackson D, Abbruzzese JL, Bareli M. 1993. Artifactual frame-shift p53 mutation at codon-249 detected with the Cyclist™ DNA sequencing method. Biotechniques 15:363-364.
34. Lerman LS, Silverstein K. 1987. Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. Methods Enzymol 155:482-501.
35. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935.
36. Lowe SW, Ruley HE, Jacks T, Housman DE. 1993. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967.
37. Nakai H, Kaneko H, Horiike S, Ariyama Y, Misawa S, Kashima K, Ishizaki K. 1994. Multiple aberrant splicing of the p53 transcript without genomic mutations around exon-intron junctions in a case of chronic myelogenous leukaemia in blast crisis: a possible navel mechanism of p53 inactivation. Br J Haematol 87:839-842.
38. Norberg T, Lennerstrand J, Inganas M, Bergh J. 1998. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 79:376-383.
39. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. 1989. Detection of polymorphisms of human DNA by gel electrophoresis as a single-stranded conformation polymorphisms. Proc Natl Acad Sci USA 86:2766-2770.
40. Ory K, Legros Y, Auguin C, Soussi T. 1994. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13:3496-3504.
41. Ozturk M, Other. 1991. p53 Mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338:1356-1359.
42. Parkin DM, Pisani P, Ferlay J. 1993. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594-606.
43. Pietenpol JA, Tokino T, Thiagalingam S, El-Deiry WS, Kinzler KW, Vogelstein B. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 91:1998-2002.
44. Puisieux A, Lim S, Groopman J, Ozturk M. 1991. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res 51:6185-6189.
45. Ren ZP, Ahmadian A, Ponten F, Nister M, Berg C, Lundeberg J, Uhlen M, Ponten J. 1997. Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. Am J Pathol 150:1791-1803.
46. Shiao YH, Buzard GS, Weghorst CM, Rice JM. 1997. DNA template as a source of artifact in the detection of p53 gene mutations using archived tissue. Biotechniques 22:608.
47. Smith ML, Chen IT, Zhan QM, Bae IS, Chen CY, Gilmer TM, Kastan MB, O'Connor PM, Fornace AJ. 1994. Interaction of the p53-regulated protein gadd45 with proliferating cell nuclear antigen. Science 266:1376-1380.
48. Soussi T. 1995. The p53 tumour suppressor gene: from molecular biology to clinical investigation. In: Cowell JK, editor. Molecular genetics of cancer. p 135-178.
49. Stolzenberg MC, Brugieres L, Gardes M, Dessarpsfreichey F, Chompret A, Bressac B, Lenoir G, Bonaitipellie C, Lemerle J, Feunteun J. 1994. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family. Oncogene 9:2799-2804.
50. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. 1989. p53 - a frequent target for genetic abnormalities in lung cancer. Science 246:491-494.
51. Tornaletti S, Pfeifer GP. 1995. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene 10:1493-1499.
52. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, Wang Z, Friedberg EC, Evans MK, Taffe BG, Bohr VA, Weeda G, Hoeijmakers JHJ, Forrester K, Harris CC. 1995. p53 Modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet 10:188-195.
53. Williams C, Norberg T, Ahmadian A, Ponten F, Bergh J, Inganas M, Lundeberg J, Uhlen M. 1998. Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets. Clin Chem 44:455-462.
54. Yin YX, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948.
55. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347.
56. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remington L, Jacks T, Brash DE. 1994. Sunburn and p53 in the onset of skin cancer. Nature 372: 773-776.